Biotechnologies news and biotechnologies widget
Tuesday, December 02, 2008 ( change date )
Pacgen Biopharmaceuticals Corporation: Pacgen Reports Second Quarter Financial Results
VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) today reported financial results from its second fiscal quarter ended September 30, 2008. Amounts unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
Marketwire.com Tuesday, December 02, 2008QLT shares buck falling market on buyback (AP)
Biotechnology company QLT Inc. said Monday its board of directors approved a buyback plan worth up to $50 million though a tender offer that offers investors up to a 32 percent premium.
yahoo.com Tuesday, December 02, 2008Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet (PR Newswire)
Vanda Pharmaceuticals Inc. reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon .
yahoo.com Tuesday, December 02, 2008Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa
[NEWS]
WASHINGTON, Dec. 2 — Population Services International (PSI) is launching a new comprehensive project that could dramatically reduce the number of African children dying every year from malaria. The program will provide free artemisinin-based combination therapies (ACT) given by local community health workers to poor children suspected of having malaria. This quick-response approach to treatment will be monitored to determine if it reduces the number of African children dying from malaria. It is estima…
LifeSciencesWorld.com Tuesday, December 02, 200838 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting
[NEWS]
IRVINE, Calif., Dec. 2 — Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that physicians from leading medical institutions including Mayo Clinic, Memorial Sloan-Kettering Cancer Center and the University of Wisconsin School of M…
LifeSciencesWorld.com Tuesday, December 02, 2008TGen and international team identify gene that could put people at risk for age-related hearing loss
PHOENIX, Ariz. - Researchers at the Translational Genomics Research Institute, working with scientists from Los Angeles and Belgium, have identified a gene that could help explain why some people lose... [WebWire - Tuesday, December 02, 2008]
Webwire Tuesday, December 02, 2008CT Colonography Offers One-Stop Screening for Cancer and Osteoporosis
CHICAGO - New research reveals that computed tomography (CT) colonography, also known as virtual colonoscopy, has the potential to screen for two diseases at once-colorectal cancer and osteoporosis, b... [WebWire - Tuesday, December 02, 2008]
Webwire Tuesday, December 02, 2008Targeted Genetics lays off staff, shifts focus
Targeted Genetics (TGEN) said today that it has cut about 10 percent of its workforce and shifted its research efforts in a bid to survive a cash crunch.
The Seattle Times Tuesday, December 02, 2008IBT Laboratories Expands its Menu of Tests for Immune Deficiency
[NEWS]
LENEXA, Kan., Dec. 2 — IBT Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing in immunology and allergy assays, announced that it has launched two tests to evaluate the response of patients whose immune systems may be compromised due to a primary immunodeficiency disorder, chemotherapy drugs, or because they are taking immuno-suppressing drugs to prevent rejection of a transplant. The company launched the two new assays, the T Cell Fx<s…
LifeSciencesWorld.com Tuesday, December 02, 2008Ahura Scientific: Ahura Scientific Wins Second Cygnus Innovation Award
WILMINGTON, MA (MARKET WIRE) Ahura Scientific, Inc., a leader in rugged, ultra-compact handheld instruments for chemical identification, today announced that it was recognized with a Cygnus Law Enforcement Group Innovation Award in the HazMAT/WMD category for its most recent product, TruDefender(TM) FT. Based on Fourier-Transform Infrared (FTIR) spectroscopy, TruDefender FT is a handheld system designed to identify unknown chemicals directly in the hotzone. Built for first responders, the instrument weighs less than 3 pounds and is rugged enough to withstand the rigors of field use. TruDefender FT complements Ahura
Marketwire.com Tuesday, December 02, 20081 2

PREVIEW
OF YOUR NEWS WIDGET
INSTALL YOUR WIDGET